Prevention of cardiovascular disease after renal transplantation

Current Opinion in Organ Transplantation

Volumn 17, Issue 4, 2012, Pages 393-400

  Svensson, My ^a   Jardine, Alan ^b   Fellström, Bengt ^c   Holdaas, Hallvard ^d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UPPSALA UNIVERSITY   (Sweden)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

cardiovascular disease; immunosuppression; renal transplantation

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; BELATACEPT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CHOLESTEROL; CORTICOSTEROID; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE PLUS SIMVASTATIN; FLUINDOSTATIN; HOMOCYSTEINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; TACROLIMUS; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANEMIA; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DYSLIPIDEMIA; EXERCISE; GRAFT RECIPIENT; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MORTALITY; OBESITY; PHYSICAL ACTIVITY; PROTEINURIA; REVIEW; RISK FACTOR; SMOKING; SMOKING CESSATION;

CARDIOVASCULAR DISEASES; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RISK ASSESSMENT; RISK FACTORS;

EID: 84864714488     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283560a3b     Document Type: Review

References (76)

1. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108:2154-2169.
2. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357:2562-2575.
3. Pilmore H, Dent H, Chang S, et al. Reduction in cardiovascular death after kidney transplantation. Transplantation 2010; 89:851-857.
4. Israni AK, Snyder JJ, Skeans MA, et al. Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study. Am J Transplant 2010; 10:338-353.
5. Kidney Disease Improving Global Outcome Transplant Work Group. Clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 (Suppl 3):S1-S155.
6. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360:1395-1407.
7. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353:238-248.
8. Kasiske BL, Guijarro C, Massy ZA, et al. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7:158-165.
9. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11:1735-1743.
10. Silver SA, Huang M, Nash MM, Prasad GV. Framingham risk score and novel cardiovascular risk factors underpredict major adverse cardiac events in kidney transplant recipients. Transplantation 2011; 92:183-189.
11. Soveri I, Holme I, Holdaas H, et al. A cardiovascular risk calculator for renal transplant recipients. Transplantation (in press).
12. van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79:1341-1352.
13. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375:2073-2081.
14. Wadei HM, Textor SC. Hypertension in the kidney transplant recipient. Transplant Rev (Orlando ) 2010; 24:105-120.
15. Ponticelli C, Cucchiari D, Graziani G. Hypertension in kidney transplant recipients. Transpl Int 2011; 24:523-533.
16. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53:217-222.
17. Jardine AG, Fellstrom B, Logan JO, et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis 2005; 46:529-536.
18. Soveri I, Holdaas H, Jardine A, et al. Renal transplant dysfunction: importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality. Nephrol Dial Transplant 2006; 21:2282-2289.
19. Kasiske BL, Anjum S, Shah R, et al. Hypertension after kidney transplantation. Am J Kidney Dis 2004; 43:1071-1081.
20. Haydar AA, Covic A, Jayawardene S, et al. Insights from ambulatory blood pressure monitoring: diagnosis of hypertension and diurnal blood pressure in renal transplant recipients. Transplantation 2004; 77:849-853.
21. Wadei HM, Amer H, Taler SJ, et al. Diurnal blood pressure changes one year after kidney transplantation: relationship to allograft function, histology, and resistive index. J Am Soc Nephrol 2007; 18:1607-1615.
22. Opelz G, Dohler B. Improved long-term outcomes after renal transplantation associated with blood pressure control. Am J Transplant 2005; 5:2725-2731.
23. Heinze G, Mitterbauer C, Regele H, et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006; 17:889-899.
24. Opelz G, Zeier M, Laux G, et al. No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 2006; 17:3257-3262.
25. Heinze G, Oberbauer R. Does size matter? Nephrol Dial Transplant 2007; 22:2275-2726.
26. Cross NB, Webster AC, Masson P, et al. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation 2009; 88:7-18.
27. Philipp T, Martinez F, Geiger H, et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant 2010; 25:967-976.
28. Mangray M, Vella JP. Hypertension after kidney transplant. Am J Kidney Dis 2011; 57:331-341.
29. Courivaud C, Kazory A, Simula-Faivre D, et al. Metabolic syndrome and atherosclerotic events in renal transplant recipients. Transplantation 2007; 83:1577-1581.
30. de Vries AP, Bakker SJ, van Son WJ, et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 2004; 4:1675-1683.
31. Bayer ND, Cochetti PT, Anil Kumar MS, et al. Association of metabolic syndrome with development of new-onset diabetes after transplantation. Transplantation 2010; 90:861-866.
32. Soveri I, Abedini S, Holdaas H, et al. Graft loss risk in renal transplant recipients with metabolic syndrome: subgroup analyses of the ALERT trial. J Nephrol 2012; 25:245-254.
33. Potluri K, Hou S. Obesity in kidney transplant recipients and candidates. Am J Kidney Dis 2010; 56:143-156.
34. Hjelmesaeth J, Hartmann A, Leivestad T, et al. The impact of early-diagnosed new-onset posttransplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006; 69:588-595.
35. Revanur VK, Jardine AG, Kingsmore DB, et al. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant 2001; 15:89-94.
36. Porrini E, Delgado P, Bigo C, et al. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis 2006; 48:134-142.
37. Jardine AG, Gaston RS, Fellstrom BC, Holdaas H. Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 2011; 378:1419-1427.
38. Vincenti F, Friman S, Scheuermann E, et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 2007; 7:1506-1514.
39. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with newonset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19:1411-1418.
40. Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005; 19:291-298.
41. Tsimihodimos V, Dounousi E, Siamopoulos KC. Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment. Am J Nephrol 2008; 28:958-973.
42. Holdaas H, Kobashigawa JA, Fellstrom B, Jardine AG. Special patient populations: Transplant recipients. In: Ballantyne CM, editor. Clinical Lipidology. Philadelphia: Elsevier; 2009. pp. 489-499.
43. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebocontrolled trial. Lancet 2003; 361:2024-2031.
44. Holdaas H, Fellstrom B, Cole E, et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005; 5:2929-2936.
45. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011; 377:2181-2192.
46. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol 2008; 51:2375-2384.
47. Tatsioni A, Chung M, Sun Y, et al. Effects of fish oil supplementation on kidney transplantation: a systematic review and meta-analysis of randomized, controlled trials. J Am Soc Nephrol 2005; 16:2462-2470.
48. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003; 75:1291-1295.
49. Fellstrom B, Jardine AG, Soveri I, et al. Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation. Am J Transplant 2005; 5:1986-1991.
50. Messa P, Ponticelli C, Berardinelli L. Coming back to dialysis after kidney transplant failure. Nephrol Dial Transplant 2008; 23:2738-2742.
51. Nankivell BJ, Kuypers DR. Diagnosis and prevention of chronic kidney allograft loss. Lancet 2011; 378:1428-1437.
52. Shamseddin MK, Knoll GA. Posttransplantation proteinuria: an approach to diagnosis and management. Clin J Am Soc Nephrol 2011; 6:1786-1793.
53. Knoll GA, Cantarovitch M, Cole E, et al. The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation study design. Nephrol Dial Transplant 2008; 23:354-358.
54. Kamar N, Rostaing L, Ignace S, Villar E. Impact of posttransplant anemia on patient and graft survival rates after kidney transplantation: a meta-analysis. Clin Transplant 2011. [Epub ahead of print]
55. Choukroun G, Kamar N, Dussol B, et al. Correction of postkidney transplant anemia reduces progression of chronic allograft nephropathy. J Am Soc Nephrol 2012; 23:380-368.
56. Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation 2011; 123:1763-1770.
57. Clarke R, Halsey J, Lewington S, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascular disease, cancer, and cause-specific mortality: meta-analysis of 8 randomized trials involving 37 485 individuals. Arch Intern Med 2010; 170:1622-1631.
58. Hurst FP, Altieri M, Patel PP, et al. Effect of smoking on kidney transplant outcomes: analysis of the United States Renal Data System. Transplantation 2011; 92:1101-1107.
59. Agarwal PK, Hellemons ME, Zelle DM, et al. Smoking is a risk factor for graft failure and mortality after renal transplantation. Am J Nephrol 2011; 34:26-31.
60. Zelle DM, Corpeleijn E, Stolk RP, et al. Low physical activity and risk of cardiovascular and all-cause mortality in renal transplant recipients. Clin J Am Soc Nephrol 2011; 6:898-905.
61. Heiwe S, Jacobson SH. Exercise training for adults with chronic kidney disease. Cochrane Database Syst Rev 2011:CD003236.
62. Johansen KL, Painter P. Exercise in individuals with CKD. Am J Kidney Dis 2012; 59:126-134.
63. Painter PL, Hector L, Ray K, et al. A randomized trial of exercise training after renal transplantation. Transplantation 2002; 74:42-48.
64. Painter PL, Hector L, Ray K, et al. Effects of exercise training on coronary heart disease risk factors in renal transplant recipients. Am J Kidney Dis 2003; 42:362-369.
65. Fox CS, Muntner P, Chen AY, et al. Use of evidence-based therapies in shortterm outcomes of ST-segment elevation myocardial infarction and non-STsegment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network registry. Circulation 2010; 121:357-365.
66. Lentine KL, Villines TC, Xiao H, et al. Cardioprotective medication use after acute myocardial infarction in kidney transplant recipients. Transplantation 2011; 91:1120-1126.
67. Pilmore HL, Skeans MA, Snyder JJ, et al. Cardiovascular disease medications after renal transplantation: results from the Patient Outcomes in Renal Transplantation study. Transplantation 2011; 91:542-551.
68. Casey MJ, Meier-Kriesche HU. Calcineurin inhibitors in kidney transplantation: friend or foe? Curr Opin Nephrol Hypertens 2011; 20:610-615.
69. Kasiske BL, de MattosF A. Flechner SM, et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008; 8:1384-1392.
70. Luan FL, Steffick DE, Ojo AO. New-onset diabetes mellitus in kidney transplant recipients discharged on steroid-free immunosuppression. Transplantation 2011; 91:334-341.
71. Vincenti F, Schena FP, Paraskevas S, et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8:307-316.
72. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248:564-577.
73. Knight SR, Morris PJ. Steroid avoidance or withdrawal after renal transplantation increases the risk of acute rejection but decreases cardiovascular risk. A meta-analysis. Transplantation 2010; 89:1-14.
74. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10:535-546.
75. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10:547-557.
76. Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 2011; 91:976-983.